Content in this section will include AAPM advocacy efforts, legislative news, public statements, etc.

FDA Announces Public Meeting to Discuss Safety and Utility of Higher-Dose Opioid Analgesics

FDA is seeking public input on the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient set...
Continue reading
Topics:

FDA MedWatch Safety Alert: Ketorolac Tromethamine Injection by Sagent Pharmaceuticals: Recall - Due to Lack of Sterility Assurance

Sagent Pharmaceuticals, announced the voluntary nationwide recall of Lot Number M813513 of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.  

Continue reading

CDC Addresses Concerns Raised in AAPM Foundation Consensus Panel Report on the Challenges of Implementing the CDC Guideline

Earlier this year, a consensus panel report addressing the challenges of implementing the CDC Guideline for Prescribing Opioids for Chronic Pain was published in Pain Medicine . The report, authored by a multidisciplinar...
Continue reading

FDA MedWatch Safety Alert: Fentanyl Transdermal System by Alvogen - Recall: Due to Product Mislabeling

 Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. The 50 mcg/h patches that were included in cartons labeled 12 mcg/h are individually labeled as 50 mcg/h.
Continue reading

Help AAPM and the AMA Opioid Task Force Identify Barriers in Treatment

As one of the organizations in the AMA Opioid Taskforce, AAPM is working with the American Medical Association (AMA) to gather information on barriers to treatment. AAPM and the AMA request 10-15 minutes of your time to ...
Continue reading

CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain

The American Society of Clinical Oncology, the American Society of Hematology, and the National Comprehensive Cancer Network® received a letter from the Centers for Disease Control and Prevention (CDC) clarifying the CDC Guideline for Prescribing Opioids for Chronic Pain on prescribing opioids to manage pain from certain conditions. 

Continue reading
Topics:

AAPM Comments on AHRQ Key Questions for Systematic Review on Management of Primary Headaches in Pregnancy

Comments from the American Academy of Pain Medicine The American Academy of Pain Medicine thanks the Agency for the opportunity to comment on The Evidence-based Practice Center Program at the Agency for Healthcare Resear...
Continue reading

FDA Identifies Harm Reported From Sudden Discontinuation of Opioid Pain Medicines

The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide. 

Continue reading
Topics:

HHS Releases Additional $487 Million to States, Territories to Expand Access to Effective Opioid Treatment; 2019 SOR Grants Will Total $1.4 Billion

 

This funding will expand access to treatment that works, especially to medication-assisted treatment (MAT) with appropriate social supports.

Continue reading
Topics:

AHRQ Seeks Input on Headaches in Pregnancy and Acute Pain

The Agency for Healthcare Research and Quality (AHRQ) has posted key questions for the systematic review on Management of Primary Headaches in Pregnancy for comment through April 11, as well as a draft technical brief on...
Continue reading

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More